@entity882 and XXXX : use of the Kim-Ray Greenfield filter to prevent thromboembolism.

@entity1 @entity0 @entity882 @entity548 @entity5 @entity49 @entity1072 @entity1151 @entity694 @entity204
The association of @entity49 and @entity5 , a well established pattern of disease, often leads to @entity1151 in an already compromised patient. Anticoagulation therapy in these @entity1 is occasionally complicated by several factors including @entity882 , which may result in a life-threatening situation of @entity1151 . Mechanical intervention may prevent @entity1151 from reaching the lungs, thereby negating the use of anticoagulants in the @entity1 with @entity882 . In this clinical trial, ten @entity1 with @entity5 and @entity882 complicated by recurrent @entity1151 received the Kim-Ray Greenfield filter. There were four @entity1 (two with @entity694 and two with @entity1072 ) and six @entity1 (four with @entity0 , one with @entity694 , and one with @entity1072 ). Pulmonary emboli were documented in all @entity1 by comparative ventilation/perfusion lung scans, arterial blood gas determinations, and chest x-ray films. In each case anticoagulation was begun, but in six of the ten @entity1 @entity548 developed and anticoagulation had to be discontinued. The Kim-Ray Greenfield filter was subsequently placed in all ten @entity1 in the infrarenal inferior vena cava (eight via a jugular approach and two via the femoral vein) without complication, and anticoagulation was discontinued. All @entity1 had follow-up to time of @entity204 , ranging from six to 26 months (mean 11 months). In no @entity1 was recurrent @entity1151 based on clinical evidence, nor in autopsy reports in three of the ten @entity1 . There should be increased usage of the Kim-Ray Greenfield filter in @entity1 with @entity5 , @entity882 , and @entity1151 .
